This study was carried out in order to evaluate possible mechanisms responsible for
tumor induction by
1-nitropyrene and to provide insights on the higher tumorigenicity of
1-nitrosopyrene than
1-nitropyrene in newborn mouse liver. The "ground mouse" technique was used to follow the development of the metabolism of
1-nitropyrene and
1-nitrosopyrene in newborn and infant mice in vivo. Equimolar doses of
1-nitropyrene and
1-nitrosopyrene were used as in the bioassay reported previously. The compounds were administered by ip injection (100 nmol, day 1; 200 nmol, day 8; 400 nmol, day 15). The
ethyl acetate soluble metabolites of
1-nitropyrene were identified as
1-aminopyrene, trans-4,5-dihydro-4,5-dihydroxy-1-nitropyrene, 1-nitropyren-3-ol, 1-nitropyren-6-ol, and 1-nitropyren-8-ol on the basis of cochromatography with synthetic standards in two different HPLC systems. Nitroreduction of
1-nitropyrene to
1-aminopyrene was observed only in 1 day old mice.
Ethyl acetate soluble metabolites of
1-nitrosopyrene were identified as
1-aminopyrene and
1-nitropyrene. The capacity of 1 day old mice to metabolize
1-nitropyrene and
1-nitrosopyrene exceeded those of 8 and 15 day old mice. The extent of nitroreduction of
1-nitrosopyrene exceeded that of
1-nitropyrene. A major
DNA adduct,
N-(deoxyguanosin-8-yl)-1-aminopyrene, was identified and quantified in liver and in lung, 24 h after
carcinogen treatment. The extents of formation of this adduct (pmol/mg of
DNA, mean of two experiments) were as follows:
1-nitropyrene (liver, 4.1; lung, 1.2);
1-nitrosopyrene (liver, 30.4; lung, 6.3).(ABSTRACT TRUNCATED AT 250 WORDS)